Strykagen is a biopharmaceutical company that develops transforming therapeutics and diagnostics for life-threatening rare muscle diseases. It offers developing therapeutics for Duchenne muscular dystrophy (DMD), merosin deficient congenital muscular dystrophy (MDC1A), becker muscular dystrophy (BMD), and limb-girdle muscular dystrophies (LGMD). The company also delivers development of protein therapeutics, clinical and pre-clinical studies, medical diagnostics, and other services.